Observational studyInternal and emergency medicine2018
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.
Observational study in Internal and emergency medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.Lipids in health and disease · 2020Pooled it
- Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis.Clinical rheumatology · 2019Pooled it
- Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.Signal transduction and targeted therapy · 2026Article
- Article
- Risk of pancreatic cancer according to glycemic status in nonalcoholic fatty liver disease: a nationwide cohort study.Scientific reports · 2025Article
- Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes.World journal of hepatology · 2023Review
- Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).Signal transduction and targeted therapy · 2022Review
- Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?Current oncology (Toronto, Ont.) · 2022Review
- Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease.Scientific reports · 2022Article
- Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Review
- Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.Cancer metastasis reviews · 2021Review
- The Provocative Roles of Platelets in Liver Disease and Cancer.Frontiers in oncology · 2021Review
- Is there a link between non-alcoholic fatty liver disease aspects and pancreatic cancer? Results of a case-matched study.Revista do Colegio Brasileiro de Cirurgioes · 2021Article
- Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs.Diagnostics (Basel, Switzerland) · 2020Review
- Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease.Current hepatology reports · 2019Article
- Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey: comment.Internal and emergency medicine · 2019Article
- p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Pancreatic cancer: risk and preventive factors.Internal and emergency medicine · 2018Article
- The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is difficult to diagnose in an early stage, and has the highest mortality of all types of cancer. Obesity, high body mass index, and increased abdominal girth are established risk factors. Some studies have postulated that there is a correlation between organ steatosis and pancreatic cancer. This study aims to explore whether nonalcoholic fatty liver disease (NAFLD) is a risk factor and a prognostic factor for pancreatic cancer. The study enrolled 557 patients (143 with and 414 without pancreatic cancer) who were diagnosed between January 2009 and December 2013. We reviewed the abdominal computed tomographic scans of the patients to confirm the diagnosis of NAFLD. Clinical parameters, laboratory data, and personal information were analyzed. NAFLD is an independent risk factor for pancreatic cancer according to adjusted multivariate logistic regression analysis (OR 2.63, 95% CI 1.24-5.58, p = 0.011). The Kaplan-Meier survival curve reveals that patients without NAFLD have longer survival than patients with NAFLD (p = 0.005, log-rank test). NAFLD is positively correlated with pancreatic cancer, a result suggesting that NAFLD may increase the incidence and risk of pancreatic cancer. Patients with pancreatic cancer and NAFLD have poorer overall survival than patients without NAFLD, perhaps, because dysregulated cytokine status leads to progression of pancreatic cancer. NAFLD may be a prognostic factor for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.